Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05290597
Title A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Innovent Biologics (Suzhou) Co. Ltd.
Age Groups: senior | adult
Covered Countries

No variant requirements are available.